Healthcare Industry News: Advanced Research Technologies
News Release - July 24, 2007
ART and Stanford Establish Collaboration on Treatment Monitoring and Diagnosis with SoftScan Optical Breast Imaging
MONTREAL, CANADA--(Healthcare Sales & Marketing Network)--Jul 24, 2007 -- ART Advanced Research Technologies Inc. ("ART")(Toronto:ARA.TO ), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today an agreement to develop and conduct clinical research with the Stanford Breast Imaging Section of Stanford University to evaluate the effectiveness of the SoftScan® optical breast imaging system in treatment monitoring and diagnosis of breast cancer.Dr. Debra Ikeda, Director of the Stanford Breast Imaging Section, is the Principal Investigator of this clinical research collaboration. In this role, she will also lead collaborative initiatives with Dr. Sanjiv Sam Gambhir, Director, Molecular Imaging Program at Stanford, the primary objective of which will be to extend SoftScan®'s clinical value into the expanding field of breast cancer probe development.
"We look forward to clinical research with SoftScan® optical breast imaging to address important unmet needs in breast cancer treatment monitoring and diagnosis. In addition, we look forward to incorporating molecular imaging techniques developed at the Clark Center into our breast cancer research," stated Dr. Ikeda, Director of the Stanford University Breast Imaging Section.
"Stanford University provides the optimum environment in North America for developing SoftScan®'s molecular imaging technology in the clinical arena. We look forward to working with Dr. Ikeda, the Stanford Breast Imaging Section, and the world-class researchers at the Clark Center/ Molecular Imaging Program at Stanford," said Mr. Sebastien Gignac, President and CEO of ART. "And because we believe that the treatment monitoring capabilities of SoftScan® molecular imaging will enable more predictable and productive drug development, we are actively seeking pharmaceutical partners to join and further expand our collaboration with Stanford," added Mr. Gignac.
In addition, results from this study will offer significant new market opportunities for ART's SoftScan® and help establish commercial partnerships with pharmaceutical companies.
About SoftScan®
The SoftScan® optical breast imaging system has been designed first as a complementary diagnostic tool to mammography, with ultimate uses in the detection and treatment monitoring of breast cancer. Its non-invasive, painless approach uses time-domain optical imaging technology, which may allow clinicians to better locate and characterize breast tumors as benign or malignant and could provide faster assessment of therapeutic effectiveness. Unlike mammography whose use must be strictly limited, SoftScan® emits no radiation and can be safely used as often as needed to monitor patients. The device was created and developed by ART Advanced Research Technologies Inc., and has obtained regulatory approvals for its commercialization in Canada and in Europe.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. eXplore Optix(TM), an optical molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed by ART in North America and by GE Healthcare in the rest of the world, with a focus in Europe and Asia, and is used by industry and academic leaders worldwide. SoftScan®, an optical medical imaging device, is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra(TM) line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca .
This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (www.sedar.com).
Source: Advanced Research Technologies
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!